The Human Epidermal Growth Factor Receptor 2 (HER2), encoded by the ERBB2 gene, represents one of the most critical and extensively studied biomarkers in modern oncology. As a transmembrane tyrosine kinase receptor, HER2 plays a foundational role in regulating cellular proliferation, survival, and differentiation. Aberrant amplification or overexpression of this receptor is a well-established driver of aggressive oncogenesis, particularly in breast and gastroesophageal malignancies. Over the past few decades, the clinical landscape has been transformed by the development of sophisticated targeted therapies aimed at disrupting the HER2 signaling axis. To support the advancement of such targeted therapeutic research and biomarker discovery, we provide flexible and reliable related analysis services utilizing protein array technology to meet various research needs. This comprehensive review delineates the structural biology and complex signaling networks of the HER2 receptor, examines the evolution of targeted therapeutic modalities including monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates, and explores the multifaceted molecular mechanisms underlying primary and acquired resistance.
Structural Biology and Ligand-Independent Signaling
HER2 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, also known as the ErbB family, which includes EGFR (HER1), HER2, HER3, and HER4. Structurally, these receptors consist of an extracellular ligand-binding domain (composed of subdomains I, II, III, and IV), a single lipophilic transmembrane segment, and an intracellular domain possessing tyrosine kinase activity. HER2 is unique among its family members due to its structural conformation. Unlike EGFR or HER3, which exist in a tethered, auto-inhibited state and require specific ligand binding to expose their dimerization arm, the extracellular domain of HER2 is constitutively held in an open, extended conformation. Subdomains I and III of HER2 tightly interact, leaving the dimerization arm in subdomain II permanently exposed and poised for interaction.
Because HER2 has no known direct activating ligand, it functions primarily as a co-receptor. Its permanently open conformation makes it the preferred heterodimerization partner for all other ligand-bound ErbB receptors. The most potent and biologically significant pairing is the HER2-HER3 heterodimer. While HER3 binds ligands such as neuregulin, it lacks intrinsic kinase activity. However, when complexed with HER2, the resulting heterodimer functions as an exceptionally powerful oncogenic unit. The trans-phosphorylation of the intracellular domains creates specific docking sites for various adaptor proteins, initiating a massive cascade of downstream intracellular signaling.
The primary downstream cascades driven by HER2 activation are the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and the Ras/Raf/Mitogen-activated protein kinase (MAPK) pathway. The PI3K/AKT axis is primarily responsible for promoting cell survival and inhibiting apoptosis, heavily driven by the abundance of PI3K docking sites on the intracellular tail of HER3. Concurrently, the MAPK pathway predominantly drives cellular proliferation and cell cycle progression. The continuous, unregulated firing of these interacting networks is the hallmark of HER2-driven malignancies.
=Figure 1. Schematic of HER2 signaling system. (Source: Gollamudi J, et al. 2016)
Pathological Implications and Diagnostic Assessment
Under physiological conditions, HER2 is expressed at low levels in various epithelial tissues, contributing to normal organogenesis and tissue repair. However, in pathology, the ERBB2 gene, located on chromosome 17q12, is frequently subject to genomic amplification. This amplification leads to the profound overexpression of the HER2 protein on the cell surface—sometimes reaching up to two million receptors per cell, compared to the tens of thousands found on normal cells. This high receptor density leads to spontaneous, ligand-independent homodimerization and constitutive kinase activation.
HER2 amplification or overexpression is most notably observed in approximately 15% to 20% of invasive breast carcinomas. Historically, HER2-positive breast cancer was associated with a highly aggressive clinical course, higher rates of visceral and central nervous system metastases, and poor overall survival. Beyond breast tissue, HER2 overexpression is also a critical driver in 15% to 25% of gastroesophageal junction and gastric adenocarcinomas, as well as a subset of colorectal, biliary tract, and salivary gland tumors.
The precise diagnostic assessment of HER2 status is paramount for determining patient eligibility for targeted therapies. The clinical gold standard relies on a dual-testing algorithmic approach utilizing immunohistochemistry (IHC) to measure protein expression on the cell membrane, and in situ hybridization (ISH)—such as fluorescence ISH (FISH)—to detect gene amplification at the chromosomal level. The standardized scoring system categorizes IHC results from 0 to 3+. Historically, only IHC 3+ or IHC 2+ with concurrent ISH amplification were classified as HER2-positive and eligible for targeted blockade. However, the oncological paradigm has recently shifted to recognize the "HER2-low" classification. Tumors scoring IHC 1+ or IHC 2+ with negative ISH results, previously categorized as HER2-negative, are now recognized as a distinct clinical entity. This low-level expression, while insufficient to drive oncogenesis on its own, provides enough receptor density to serve as an anchor for novel, highly potent targeted delivery systems.
Evolution of Targeted Therapeutic Interventions
The clinical management of HER2-driven malignancies has been revolutionized by the sequential development of three major classes of targeted agents: monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates.
Monoclonal antibodies were the first breakthrough in targeting the extracellular domain of HER2. These engineered immunoglobulins function through multiple mechanisms of action. By binding to subdomain IV, certain antibodies inhibit the shedding of the extracellular domain and prevent ligand-independent homodimerization. Other antibodies are designed to bind specifically to subdomain II, effectively blocking the crucial heterodimerization of HER2 with HER3. Beyond simple receptor blockade, a critical mechanism of action for these antibodies is the recruitment of the innate immune system. By coating the tumor cell, the Fc portion of the antibody attracts natural killer (NK) cells and macrophages, initiating robust antibody-dependent cellular cytotoxicity (ADCC) and ultimately leading to targeted tumor cell lysis.
Tyrosine Kinase Inhibitors (TKIs) represent a different approach, utilizing small molecules capable of crossing the plasma membrane to target the intracellular kinase domain. These agents act as competitive inhibitors, binding to the ATP-binding pocket of the HER2 receptor (and often simultaneously targeting EGFR or other ErbB family members). By preventing ATP binding, TKIs completely shut down the autophosphorylation process and immediately halt all downstream signal transduction. TKIs are particularly valuable in the clinical setting because their small molecular weight allows them to penetrate the blood-brain barrier more effectively than large monoclonal antibodies, making them crucial for managing central nervous system metastases.
The most recent and transformative advancement in this field is the development of Antibody-Drug Conjugates (ADCs). ADCs are complex tripartite molecules consisting of a HER2-targeting monoclonal antibody, a stable chemical linker, and a highly potent cytotoxic payload (such as a topoisomerase inhibitor or a microtubule-disrupting agent). The antibody acts as a sophisticated homing device, navigating the systemic circulation to bind specifically to the HER2 receptor on the tumor cell surface. Upon binding, the entire receptor-ADC complex is internalized into the cell via endocytosis. Once inside the lysosome, the linker is cleaved, releasing the massive cytotoxic payload directly within the tumor cell, minimizing systemic toxicity. Crucially, modern ADCs utilize membrane-permeable payloads. Once the targeted cell is destroyed, the payload can diffuse outward into the surrounding tumor microenvironment, destroying adjacent tumor cells regardless of their individual HER2 expression levels. This phenomenon, known as the "bystander effect," is the primary reason ADCs demonstrate profound efficacy even in highly heterogeneous, HER2-low tumors.
Figure 2. Mechanism of action of anti-HER2 ADCs. (Source: Díaz-Rodríguez E, et al. 2021)
Mechanisms of Molecular Resistance
Despite the unprecedented clinical success of these targeted modalities, the durability of response is frequently limited by the emergence of acquired resistance. The tumor architecture is highly dynamic, and selective therapeutic pressure inevitably drives molecular adaptations that allow the tumor cells to evade targeted blockade.
One primary mechanism of resistance involves structural alterations to the HER2 receptor itself. In some advanced tumors, the extracellular domain of HER2 is cleaved by cell surface metalloproteinases. This shedding leaves behind a truncated, membrane-bound fragment known as p95HER2. Because p95HER2 lacks the extracellular binding epitopes required for monoclonal antibodies and ADCs to attach, it renders these therapies entirely ineffective. However, the intracellular kinase domain of p95HER2 remains fully intact and constitutively active, driving aggressive tumor growth. In these specific scenarios, the tumor remains reliant on HER2 signaling, making intracellular Tyrosine Kinase Inhibitors the only viable targeted option.
Another widespread mechanism of escape is the compensatory upregulation of parallel, alternative signaling pathways. When HER2 is successfully blocked, tumor cells often amplify the expression of other receptor tyrosine kinases, such as the Hepatocyte Growth Factor Receptor (c-MET), Insulin-like Growth Factor 1 Receptor (IGF-1R), or Fibroblast Growth Factor Receptor (FGFR). These alternative receptors bypass the HER2 blockade entirely, reactivating the critical PI3K and MAPK pathways and restoring cellular proliferation. Additionally, steric hindrance can prevent drug binding; for example, the overexpression of large, heavily glycosylated mucin proteins (like MUC4) on the cell surface can physically mask the HER2 epitope, preventing the physical attachment of therapeutic antibodies.
Finally, mutations occurring downstream within the signaling cascades can render upstream HER2 blockade irrelevant. Activating mutations in the PIK3CA gene, which encodes the catalytic subunit of PI3K, or the loss of the tumor suppressor PTEN, are highly prevalent in advanced breast and gastric cancers. These genomic alterations result in the constitutive, autonomous firing of the PI3K/AKT survival pathway, completely independent of whatever state the upstream HER2 receptor is in. Overcoming this profound resistance requires rational combination strategies, often coupling HER2-directed agents with specific PI3K or mTOR pathway inhibitors.
Frequently Asked Questions (FAQs)
Historically, only tumors with high levels of HER2 amplification were eligible for targeted therapies. The "HER2-low" classification identifies a newly recognized subset of tumors with low-level HER2 expression. While this low expression may not drive the cancer's growth independently, it provides enough cellular targets for modern Antibody-Drug Conjugates (ADCs) to bind and deliver potent cytotoxic payloads, opening new treatment avenues for a large population of patients.
Tumors are often heterogeneous, meaning some cells express HER2 while neighboring cells do not. ADCs overcome this via the "bystander effect." Once the ADC binds to a HER2-expressing cell, is internalized, and releases its membrane-permeable cytotoxic payload, that payload can diffuse out of the dying cell and eliminate adjacent tumor cells, regardless of whether those neighboring cells express HER2.
Yes. The blood-brain barrier often prevents large molecules, such as monoclonal antibodies, from entering the central nervous system effectively. TKIs, however, are small molecules that can more readily penetrate the blood-brain barrier, making them a crucial therapeutic option for managing central nervous system metastases in HER2-driven malignancies.
The PI3K/AKT pathway is a major downstream survival cascade typically activated by the HER2 receptor. If mutations occur downstream—such as activating mutations in PIK3CA or the loss of the PTEN tumor suppressor—this survival pathway remains permanently active, independent of the HER2 receptor's status. In these cases, blocking HER2 is no longer sufficient to halt tumor growth, necessitating combination therapies.
References
- Gollamudi J, et al. Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab. Cancer Manag Res. 2016 Feb 18;8:21-31.
- Díaz-Rodríguez E, et al. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers (Basel). 2021 Dec 29;14(1):154.
- Baselga J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19.
- Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9-20.